|
1
|
Edgren G, Adami HO, Weiderpass E and Nyrén
O: A global assessment of the oesophageal adenocarcinoma epidemic.
Gut. 62:1406–1414. 2013. View Article : Google Scholar
|
|
2
|
UK CR: Oesophageal Cancer. 2020.
|
|
3
|
Shitara K, Muro K, Matsuo K, Ura T,
Takahari D, Yokota T, Sawaki A, Kawai H, Ito S, Munakata M and
Sakata Y: Chemotherapy for patients with advanced gastric cancer
with performance status 2. Gastrointest Cancer Res. 3:220–224.
2009.
|
|
4
|
Offman J, Pesola F and Sasieni P: Trends
and projections in adenocarcinoma and squamous cell carcinoma of
the oesophagus in England from 1971 to 2037. Br J Cancer.
118:1391–1398. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Merchant SJ, Brogly SB, Booth CM, Goldie
C, Nanji S, Patel SV, Lajkosz K and Baxter NN: Palliative care and
symptom burden in the last year of life: A population-based study
of patients with gastrointestinal cancer. Ann Surg Oncol.
26:2336–2345. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Handforth C, Clegg A, Young C, Simpkins S,
Seymour MT, Selby PJ and Young J: The prevalence and outcomes of
frailty in older cancer patients: A systematic review. Ann Oncol.
26:1091–1101. 2015. View Article : Google Scholar
|
|
7
|
Besharat S, Jabbari A, Semnani S, Keshtkar
A and Marjani J: Inoperable esophageal cancer and outcome of
palliative care. World J Gastroenterol. 14:3725–3728. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fontana E and Smyth EC: Novel targets in
the treatment of advanced gastric cancer: A perspective review.
Ther Adv Med Oncol. 8:113–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murad AM, Santiago FF, Petroianu A, Rocha
PR, Rodrigues MA and Rausch M: Modified therapy with
5-fluorouracil, doxorubicin, and methotrexate in advanced gastric
cancer. Cancer. 72:37–41. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Partnership HQI: National
Oesophago-Gastric Cancer Audit-An audit of the care received by
people with oesophago-gastric cancer and oesophageal high grade
dysplasia in England and Wales. 2019.
|
|
11
|
Swinson D, Hingorani M, Stokes Z, Dent J,
Guptal K, Chatterjee A, Kamposioras K, Grumett SA, Khan M, Marshall
H, et al: Best supportive care (BSC) with or without low-dose
chemotherapy (chemo) in frail elderly patients with advanced
gastroesophageal cancer (aGOAC): The uncertain randomization of the
GO2 phase III trial. J Clin Oncol. 37:4051. 2019. View Article : Google Scholar
|
|
12
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemo-therapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR;
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Researc: Capecitabine and oxaliplatin for advanced
esophagogastric cancer. N Engl J Med. 358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shitara K, Van Cutsem E, Bang YJ, Fuchs C,
Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, et al:
Efficacy and safety of pembrolizumab or pembrolizumab plus
chemotherapy vs chemotherapy alone for patients with first-line,
advanced gastric cancer: The KEYNOTE-062 phase 3 randomized
clinical trial. JAMA Oncol. 6:1571–1580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moehler M, Shitara S, Garrido M, Salman P,
Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A,
Liu T, et al: LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo)
versus chemo as first-line (1L) treatment for advanced gastric
cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal
adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann
Oncol. 31(Suppl 4): S11912020. View Article : Google Scholar
|
|
16
|
Hall PS, Lord SR, Collinson M, Marshall H,
Jones M, Lowe C, Howard H, Swinson D, Velikova G, Anthoney A, et
al: A randomised phase II trial and feasibility study of palliative
chemotherapy in frail or elderly patients with advanced
gastro-esophageal cancer (321GO). Br J Cancer. 116:472–478. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Swaminathan D and Swaminathan V: Geriatric
oncology: Problems with under-treatment within this population.
Cancer Biol Med. 12:275–283. 2015.
|
|
18
|
Trumper M, Ross P, Cunningham D, Norman
AR, Hawkins R, Seymour M, Harper P, Iveson T, Nicolson M and
Hickish T: Efficacy and tolerability of chemotherapy in elderly
patients with advanced oesophago-gastric cancer: A pooled analysis
of three clinical trials. Eur J Cancer. 42:827–834. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wildiers H, Heeren P, Puts M, Topinkova E,
Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E,
Colloca G, et al: International society of geriatric oncology
consensus on geriatric assessment in older patients with cancer. J
Clin Oncol. 32:2595–2603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wagner AD, Syn NL, Moehler M, Grothe W,
Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev.
8:CD0040642017.PubMed/NCBI
|
|
21
|
Waddell T, Chau I, Cunningham D, Gonzalez
D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G,
Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arends J: Struggling with nutrition in
patients with advanced cancer: Nutrition and nourishment-focusing
on metabolism and supportive care. Annals of Oncology. 29(Suppl 2):
ii27–ii34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Amarya S, Singh K and Sabharwal M: Changes
during aging and their association with malnutrition. J Clin
Gerontol Geriat. 6:78–84. 2015. View Article : Google Scholar
|
|
24
|
Barnett K, Mercer SW, Norbury M, Watt G,
Wyke S and Guthrie B: Epidemiology of multimorbidity and
implications for health care, research, and medical education: A
cross-sectional study. Lancet. 380:37–43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cereda E, Pedrolli C, Klersy C, Bonardi C,
Quarleri L, Cappello S, Turri A, Rondanelli M and Caccialanza R:
Nutritional status in older persons according to healthcare
setting: A systematic review and meta-analysis of prevalence data
using MNA(®). Clin Nutr. 35:1282–1290. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boniface MM, Wani SB, Schefter TE, Koo PJ,
Meguid C, Leong S, Kaplan JB, Wingrove LJ and McCarter MD:
Multidisciplinary management for esophageal and gastric cancer.
Cancer Manag Res. 8:39–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mills S, Buchanan D, Guthrie B, Donnan P
and Smith B: Factors affecting use of unscheduled care for people
with advanced cancer: A retrospective cohort study in Scotland. Br
J Gen Pract. 69:e860–e868. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dalhammar K, Malmström M, Schelin M,
Falkenback D and Kristensson J: The impact of initial treatment
strategy and survival time on quality of end-of-life care among
patients with oesophageal and gastric cancer: A population-based
cohort study. PLoS One. 15:e02350452020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Srivastava P: The benefits of early
integration of palliative care as a part of standard outpatient
oncology care. J Clin Oncol. 32:182014. View Article : Google Scholar
|
|
30
|
Vandebroek AJV and Schrijvers D:
Nutritional issues in anti-cancer treatment. Ann Oncol. 19:v52–v55.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Laviano A, Di Lazzaro L and Koverech A:
Nutrition support and clinical outcome in advanced cancer patients.
Proc Nutr Soc. 77:388–393. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Eyigor S and Akdeniz S: Is exercise
ignored in palliative cancer patients? World J Clin Oncol.
5:554–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wildes TM, Dua P, Fowler SA, Miller JP,
Carpenter CR, Avidan MS and Stark S: Systematic review of falls in
older adults with cancer. J Geriatr Oncol. 6:70–83. 2015.
View Article : Google Scholar :
|
|
34
|
Hurria A, Togawa K, Mohile SG, Owusu C,
Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, et
al: Predicting chemotherapy toxicity in older adults with cancer: A
prospective multicenter study. J Clin Oncol. 29:3457–3465. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wildes TM, Ruwe AP, Fournier C, Gao F,
Carson KR, Piccirillo JF, Tan B and Colditz GA: Geriatric
assessment is associated with completion of chemotherapy, toxicity,
and survival in older adults with cancer. J Geriatr Oncol.
4:227–234. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Doganay E and Moorthy K: Prehabilitation
for esophagectomy. J Thorac Dis. 11(Suppl 5): S632–S638. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Faithfull S, Turner L, Poole K, Joy M,
Manders R, Weprin J, Winters-Stone K and Saxton J: Prehabilitation
for adults diagnosed with cancer: A systematic review of long-term
physical function, nutrition and patient-reported outcomes. Eur J
Cancer Care (Engl). 28:e130232019. View Article : Google Scholar
|
|
38
|
Minnella EM, Awasthi R, Loiselle SE,
Agnihotram RV, Ferri LE and Carli F: Effect of exercise and
nutrition prehabilitation on functional capacity in esophagogastric
cancer surgery: A randomized clinical trial. JAMA Surg.
153:1081–1089. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hall CC, Cook J, Maddocks M, Skipworth
RJE, Fallon M and Laird BJ: Combined exercise and nutritional
rehabilitation in outpatients with incurable cancer: A systematic
review. Support Care Cancer. 27:2371–2384. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cancer Research UK: Improving Cancer
Treatment and Care for an Ageing Population: Cancer Research UK,
London. 2018, https://www.cancerresearchuk.org/sites/default/files/advancing_care_advancing_years_full_report.pdf.
Accessed November 4, 2020.
|
|
41
|
Soto-Perez-de-Celis E, Li D, Sun CL, Kim
K, Twardowski P, Fakih M, Chung VM, Cristea CM, Lim D, Yuan Y, et
al: Patient-defined goals and preferences among older adults with
cancer starting chemotherapy (CT). J Clin Oncol. 36:100092018.
View Article : Google Scholar
|
|
42
|
Cancer Research UK: Cancer mortality by
age. https://www.cancer-researchuk.org/health-professional/cancer-statistics/mortality/age.
Accessed November 3, 2020.
|
|
43
|
Popescu RA, Norman A, Ross PJ, Parikh B
and Cunningham D: Adjuvant or palliative chemotherapy for
colorectal cancer in patients 70 years or older. J Clin Oncol.
17:2412–2418. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Al-Batran SE, Pauligk C, Homann N,
Hartmann JT, Moehler M, Probst S, Rethwisch V,
Stoehlmacher-Williams J, Prasnikar N, Hollerbach S, et al: The
feasibility of triple-drug chemotherapy combination in older adult
patients with oesophagogastric cancer: A randomised trial of the
arbeitsgemeinschaft internistische onkologie (FLOT65+). Eur J
Cancer. 49:835–842. 2013. View Article : Google Scholar
|
|
45
|
Morley JE, Vellas B, van Kan GA, Anker SD,
Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, et
al: Frailty consensus: A call to action. J Am Med Dir Assoc.
14:392–397. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kelly CM and Shahrokni A: Moving beyond
karnofsky and ECOG performance status assessments with New
technologies. J Oncol. 2016:61865432016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kirkhus L, Šaltytė Benth J, Rostoft S,
Grønberg BH, Hjermstad MJ, Selbæk G, Wyller TB, Harneshaug M and
Jordhøy MS: Geriatric assessment is superior to oncologists'
clinical judgement in identifying frailty. Br J Cancer.
117:470–477. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rockwood K, Song X, MacKnight C, Bergman
H, Hogan DB, McDowell I and Mitnitski A: A global clinical measure
of fitness and frailty in elderly people. CMAJ. 173:489–495. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Soubeyran P, Bellera CA, Gregoire F, Blanc
J, Ceccaldi J, Mertens CBB, Mathoulin-Pélissier S, Fonck M and
Rainfray M: Validation of a screening test for elderly patients in
oncology. J Clin Oncol. 26:20568. 2008. View Article : Google Scholar
|
|
50
|
Saliba D, Elliott M, Rubenstein LZ,
Solomon DH, Young RT, Kamberg CJ, Roth C, MacLean CH, Shekelle PG,
Sloss EM and Wenger NS: The vulnerable elders survey: A tool for
identifying vulnerable older people in the community. J Am Geriatr
Soc. 49:1691–1699. 2001. View Article : Google Scholar
|
|
51
|
Overcash JA, Beckstead J, Extermann M and
Cobb S: The abbreviated comprehensive geriatric assessment (aCGA):
A retrospective analysis. Crit Rev Oncol Hematol. 54:129–136. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Steverink N, Slaets J, Schuurmans H and
Lis M: Measuring frailty: Developing and testing the GFI (Groningen
Frailty Indicator). Gerontologist. 41:236–237. 2001.
|
|
53
|
Rubenstein LZ, Stuck AE, Siu AL and
Wieland D: Impacts of geriatric evaluation and management programs
on defined outcomes: Overview of the evidence. J Am Geriatr Soc.
39(Suppl): 8S–18S. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li D, Sun CL, Kim H, Chung V, Koczywas M,
Fakih M, Chao J, Chien L, Charles K, dos Hughes SFS, et al:
Geriatric assessment-driven intervention (GAIN) on chemotherapy
toxicity in older adults with cancer: A randomized controlled
trial. J Clin Oncol. 38:120102020. View Article : Google Scholar
|
|
55
|
Kalsi T, Babic-Illman G, Ross PJ, Maisey
NR, Hughes S, Fields P, Martin FC, Wang Y and Harari D: The impact
of comprehensive geriatric assessment interventions on tolerance to
chemotherapy in older people. Br J Cancer. 112:1435–1444. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mangoni AA and Jackson SH: Age-related
changes in pharmaco-kinetics and pharmacodynamics: Basic principles
and practical applications. Br J Clin Pharmacol. 57:6–14. 2004.
View Article : Google Scholar
|
|
57
|
Cashman J, Wright J and Ring A: The
treatment of co-morbidities in older patients with metastatic
cancer. Support Care Cancer. 18:651–655. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Steinman MA and Hanlon JT: Managing
medications in clinically complex elders: 'There's got to be a
happy medium'. JAMA. 304:1592–1601. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chu MP, Hecht JR, Slamon D, Wainberg ZA,
Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, et al:
Association of proton pump inhibitors and capecitabine efficacy in
advanced gastro-esophageal cancer: Secondary Analysis of the
TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 3:767–773.
2017.
|
|
60
|
Mislang AR, Di Donato S, Hubbard J,
Krishna L, Mottino G, Bozzetti F and Biganzoli L: Nutritional
management of older adults with gastrointestinal cancers: An
International society of geriatric oncology (SIOG) review paper. J
Geriatr Oncol. 9:382–392. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Pressoir M, Desné S, Berchery D, Rossignol
G, Poiree B, Meslier M, Traversier S, Vittot M, Simon M, Gekiere
JP, et al: Prevalence, risk factors and clinical implications of
malnutrition in french comprehensive cancer centres. Br J Cancer.
102:966–971. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Andreyev HJN, Norman AR, Oates J and
Cunningham D: Why do patients with weight loss have a worse outcome
when undergoing chemotherapy for gastrointestinal malignancies? Eur
J Cancer. 34:503–509. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ross P, Ashley S, Norton A, Priest K,
Waters JS, Eisen T, Smith IE and O'Brien ME: Do patients with
weight loss have a worse outcome when undergoing chemotherapy for
lung cancers? Br J Cancer. 90:1905–1911. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Persson C and Glimelius B: The relevance
of weight loss for survival and quality of life in patients with
advanced gastrointestinal cancer treated with palliative
chemotherapy. Anticancer Res. 22:3661–3668. 2002.
|
|
65
|
Bozzetti F; SCRINIO Working Group:
Screening the nutritional status in oncology: A preliminary report
on 1,000 outpatients. Support Care Cancer. 17:279–284. 2009.
View Article : Google Scholar
|
|
66
|
Doherty TJ: Invited Review: Aging and
sarcopenia. J Appl Physiol (1985). 95:1717–1727. 2003. View Article : Google Scholar
|
|
67
|
Rémond D, Shahar DR, Gille D, Pinto P,
Kachal J, Peyron MA, Dos Santos CN, Walther B, Bordoni A, Dupont D,
et al: Understanding the gastrointestinal tract of the elderly to
develop dietary solutions that prevent malnutrition. Oncotarget.
6:13858–13898. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Qiu M, Zhou YX, Jin Y, Wang ZX, Wei XL,
Han HY, Ye WF, Zhou ZW, Zhang DS, Wang FH, et al: Nutrition support
can bring survival benefit to high nutrition risk gastric cancer
patients who received chemotherapy. Support Care Cancer.
23:1933–1939. 2015. View Article : Google Scholar
|
|
69
|
Hurria A, Brogan K, Panageas KS,
Jakubowski A, Zauderer M, Pearce C, Norton L, Howard J and Hudis C:
Change in cycle 1 to cycle 2 haematological counts predicts
toxicity in older patients with breast cancer receiving adjuvant
chemotherapy. Drugs Aging. 22:709–715. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hall PS, Swinson D, Waters JS, Wadsley J,
Falk S, Roy R, Tillett T, Nicoll J, Cummings S, Grumett SA, et al:
Optimizing chemotherapy for frail and elderly patients (pts) with
advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.
J Clin Oncol. 37:40062019. View Article : Google Scholar
|
|
71
|
Extermann M, Boler I, Reich RR, Lyman GH,
Brown RH, DeFelice J, Levine RM, Lubiner ET, Reyes P, Schreiber FJ
III and Balducci L: Predicting the risk of chemotherapy toxicity in
older patients: The chemotherapy risk assessment scale for high-age
patients (CRASH) score. Cancer. 118:3377–3386. 2012. View Article : Google Scholar
|
|
72
|
Zhang J, Liao X, Feng J, Yin T and Liang
Y: Prospective comparison of the value of CRASH and CARG toxicity
scores in predicting chemotherapy toxicity in geriatric oncology.
Oncol Lett. 18:4947–4955. 2019.PubMed/NCBI
|
|
73
|
Wildiers H, Mauer M, Pallis A, Hurria A,
Mohile SG, Luciani A, Curigliano G, Extermann M, Lichtman SM,
Ballman K, et al: End points and trial design in geriatric oncology
research: a joint European organisation for research and treatment
of cancer-Alliance for clinical trials in oncology-international
society of geriatric oncology position article. J Clin Oncol.
31:3711–3718. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Santini D, Graziano F, Catalano V, Di Seri
M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B,
Vincenzi B, et al: Weekly oxaliplatin, 5-fluorouracil and folinic
acid (OXALF) as first-line chemotherapy for elderly patients with
advanced gastric cancer:. Results of a phase II trial BMC Cancer.
6:1252006.
|
|
75
|
Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY,
Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, et al: A randomised
multicentre phase II trial of capecitabine vs S-1 as first-line
treatment in elderly patients with metastatic or recurrent
unresectable gastric cancer. Br J Cancer. 99:584–590. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
di Bartolomeo M, Bajetta E, de Braud F,
Bochicchio AM, Gebbia V, Bozzetti F, Doci R, Bonfanti G and
Cozzaglio L: Phase II study of the etoposide, leucovorin and
fluorouracil combination for patients with advanced gastric cancer
unsuitable for aggressive chemotherapy. Oncology. 52:41–44. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Cascinu S, Fedeli A and Catalano G:
Etoposide, leucovorin, 5-fluo-rouracil and interferon alpha-2b in
elderly gastric cancer patients: A pilot study. Cancer Chemother
Pharmacol. 34:72–74. 1994. View Article : Google Scholar
|
|
78
|
Tebbutt NC, Norman A, Cunningham D, Iveson
T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y
and Hill M: A multicentre, randomised phase III trial comparing
protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI
5-FU plus mitomycin C in patients with inoperable oesophagogastric
cancer. Ann Oncol. 13:1568–1575. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Jatoi A, Foster NR, Egner JR, Burch PA,
Stella PJ, Rubin J, Dakhil SR, Sargent DJ, Murphy BR and Alberts
SR: Older versus younger patients with metastatic adenocarcinoma of
the esophagus, gastroesophageal junction, and stomach: A pooled
analysis of eight consecutive North Central Cancer Treatment Group
(NCCTG) trials. Int J Oncol. 36:601–606. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Rivera F, Massutí B, Salcedo M, Sastre J,
Martínez Galán J, Valladares-Ayerbes M, Serrano R, García de
Paredes ML, Manzano JL, Galán M, et al: Phase II trial of miniDOX
(reduced dose docetaxel-oxaliplatin-capecitabine) in 'suboptimal'
patients with advanced gastric cancer (AGC). TTD. 08–02. Cancer
Chemother Pharmacol. 75:319–324. 2015. View Article : Google Scholar
|
|
81
|
Smyth EC, Verheij M, Allum W, Cunningham D
and Cervantes A: Gastric cancer: ESMO clinical practice guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 27(Suppl 5):
v38–v49. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Seymour MT, Thompson LC, Wasan HS,
Middleton G, Brewster AE, Shepherd SF, O'Mahony MS, Maughan TS,
Parmar M, Langley RE, et al: Chemotherapy options in elderly and
frail patients with metastatic colorectal cancer (MRC FOCUS2): An
open-label, randomised factorial trial. Lancet. 377:1749–1759.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Salati M, Di Emidio K, Tarantino V and
Cascinu S: Second-line treatments: Moving towards an opportunity to
improve survival in advanced gastric cancer? ESMO. Open
2:e0002062017. View Article : Google Scholar
|
|
84
|
Sugimoto A, Nishida T, Osugi N, Takahashi
K, Mukai K, Nakamatsu D, Matsubara T, Hayashi S, Yamamoto M,
Nakajima S, et al: Prediction of survival benefit when deciding
between chemotherapy and best supportive therapy in elderly
patients with advanced gastric cancer: A retrospective cohort
study. Mol Clin Oncol. 10:83–91. 2019.PubMed/NCBI
|
|
85
|
Kawazoe A, Fukuoka S, Nakamura Y, Kuboki
Y, Mikamoto Y, Shima H, Fujishiro N, Higuchi T, Wakabayashi M,
Nomura S, et al: An open-label phase II study of lenvatinib plus
pembrolizumab in patients with advanced gastric cancer (EPOC1706).
J Clin Oncol. 38:3742020. View Article : Google Scholar
|
|
86
|
Dutton SJ, Ferry DR, Blazeby JM, Abbas H,
Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A,
Falk S, et al: Gefitinib for oesophageal cancer progressing after
chemotherapy (COG): A phase 3, multicentre, double-blind,
placebo-controlled randomised trial. Lancet Oncol. 15:894–904.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Thuss-Patience PC, Kretzschmar A, Bichev
D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G
and Reichardt P: Survival advantage for irinotecan versus best
supportive care as second-line chemotherapy in gastric cancer-a
randomised phase III study of the Arbeitsgemeinschaft
Internistische Onkologie (AIO). Eur J Cancer. 47:2306–2314. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Ford HE, Marshall A, Bridgewater JA,
Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S,
Middleton GW, et al: Docetaxel versus active symptom control for
refractory oesophagogastric adenocarcinoma (COUGAR-02): An
open-label, phase 3 randomised controlled trial. Lancet Oncol.
15:78–86. 2014. View Article : Google Scholar
|
|
89
|
Shitara K, Doi T, Dvorkin M, Mansoor W,
Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova
V, et al: Trifluridine/tipiracil versus placebo in patients with
heavily pretreated metastatic gastric cancer (TAGS): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.
19:1437–1448. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Parikh JD, Hollingsworth KG, Wallace D,
Blamire AM and MacGowan GA: Normal age-related changes in left
ventricular function: Role of afterload and subendocardial
dysfunction. Int J Cardiol. 223:306–312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar
|
|
92
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Elias R, Morales J, Rehman Y and Khurshid
H: Immune check-point inhibitors in older adults. Curr Oncol Rep.
18:472016. View Article : Google Scholar
|
|
94
|
Shitara K, Özgüroğlu M, Bang YJ, Di
Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic
C, Chung HC, et al: Pembrolizumab versus paclitaxel for previously
treated, advanced gastric or gastro-oesophageal junction cancer
(KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial.
Lancet. 392:123–133. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Adamson D, Byrne A, Porter C, Blazeby J,
Griffiths G, Nelson A, Sewell B, Jones M, Svobodova M, Fitzsimmons
D, et al: Palliative radiotherapy after oesophageal cancer stenting
(ROCS): A multi-centre, open-label, phase 3 randomised controlled
trial. Lancet Gastroenterol Hepatol. Feb 18–2021.Epub ahead of
print. View Article : Google Scholar
|
|
96
|
Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y,
Cao Y, Jiao X, Sun T, Pang Y, et al: Early interdisciplinary
supportive care in patients with previously untreated metastatic
esophagogastric cancer: A Phase III randomized controlled trial. J
Clin Oncol. 39:748–756. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Lord SR, Hall PS and Seymour MT: Are we
representing the true population in oncology trials? Ann Oncol.
20:20222009. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hempenius L, Slaets JP, Boelens MA, van
Asselt DZ, de Bock GH, Wiggers T and van Leeuwen BL: Inclusion of
frail elderly patients in clinical trials: Solutions to the
problems. J Geriatr Oncol. 4:26–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Whelehan S, Lynch O, Treacy N, Gleeson C,
Oates A and O'Donovan A: Optimising clinical trial design in older
cancer patients. Geriatrics (Basel). 3:342018. View Article : Google Scholar
|
|
100
|
Hurria A, Levit LA, Dale W, Mohile SG,
Muss HB, Fehrenbacher L, Magnuson A, Lichtman SM, Bruinooge SS,
Soto-Perez-de-Celis E, et al: Improving the evidence base for
treating older adults with cancer: American society of clinical
oncology statement. J Clin Oncol. 33:3826–3833. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Hironaka S, Ueda S, Yasui H, Nishina T,
Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki
T, et al: Randomized, open-label, phase III study comparing
irinotecan with paclitaxel in patients with advanced gastric cancer
without severe peritoneal metastasis after failure of prior
combination chemotherapy using fluoropyrimidine plus platinum: WJOG
4007 trial. J Clin Oncol. 31:4438–4444. 2013. View Article : Google Scholar : PubMed/NCBI
|
